Cumberland Pharmaceutical... (CPIX)
4.77
0.24 (5.30%)
At close: Apr 17, 2025, 3:59 PM
4.70
-1.47%
After-hours: Apr 17, 2025, 07:28 PM EDT
Cumberland Pharmaceuticals Revenue Breakdown
| Period Ending | Sep 30, 2024 | Mar 31, 2024 |
|---|---|---|
| Product - Other Revenue | 624.2K | 275.33K |
| Product - Other Revenue Growth | +126.71% | n/a |
| Product - Vibativ Revenue | 1.03M | 1.61M |
| Product - Vibativ Revenue Growth | -35.97% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|
| Non-Us Revenue | 1.1M | 1.5M | 2.2M | 2.4M | 1.5M | 2.1M |
| Non-Us Revenue Growth | -26.67% | -31.82% | -8.33% | +60.00% | -28.57% | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 7.07M | 7.18M | 6.71M | 7.45M | 7.09M | 7.04M | 6.78M | 6.89M | 6.28M | 6.76M | 6.92M | 6.72M | 5.84M | 6.22M | 6.02M | 7.19M | 5.97M | 6.06M | 5.74M | 8.73M | 7.99M | 7.68M | 7.79M | 9.38M | 6.87M | 7.41M | 7M | 8.79M | 8.32M | 7.01M | 7.4M | 6.71M | 5.48M | 5.15M | 5.78M | 5.37M | 5.4M | 5.66M | 5.18M |
| Selling, General, and Administrative Revenue Growth | -1.46% | +6.93% | -9.91% | +5.14% | +0.64% | +3.92% | -1.61% | +9.73% | -7.16% | -2.26% | +2.95% | +15.04% | -6.09% | +3.34% | -16.33% | +20.50% | -1.44% | +5.44% | -34.19% | +9.31% | +3.95% | -1.39% | -16.96% | +36.54% | -7.28% | +5.85% | -20.40% | +5.74% | +18.68% | -5.34% | +10.31% | +22.46% | +6.48% | -10.91% | +7.68% | -0.70% | -4.52% | +9.35% | n/a |
| Research and Development Revenue | 1.31M | 1.06M | 1.16M | 1.26M | 1.92M | 1.15M | 1.5M | 1.41M | 1.71M | 1.82M | 1.75M | 1.61M | 1.45M | 1.36M | 1.26M | 1.4M | 1.23M | 1.42M | 1.72M | 2.08M | 1.28M | 1.46M | 1.27M | 2.69M | 1.31M | 1.45M | 1.87M | 979.41K | 943.16K | 1.08M | 898.36K | 1.16M | 644.66K | 678.78K | 706.47K | 403.13K | 757.44K | 828.07K | 1.86M |
| Research and Development Revenue Growth | +23.31% | -8.55% | -8.42% | -34.29% | +68.10% | -23.65% | +6.67% | -17.99% | -6.00% | +4.50% | +8.20% | +10.93% | +6.87% | +8.19% | -10.15% | +13.74% | -13.45% | -17.48% | -17.18% | +62.74% | -12.37% | +15.05% | -52.87% | +105.92% | -9.95% | -22.64% | +91.43% | +3.84% | -12.70% | +20.27% | -22.61% | +80.06% | -5.03% | -3.92% | +75.25% | -46.78% | -8.53% | -55.46% | n/a |
| Sales and Marketing Revenue | 4.4M | 4.25M | 4.15M | 4.76M | 4.74M | 4.67M | 4.28M | 3.38M | 4.11M | 4.56M | 4.61M | 3.31M | 3.8M | 4.12M | 3.79M | 3.6M | 3.59M | 3.87M | 3.71M | 5.59M | 5.56M | 5.15M | 5.12M | 5.71M | 4.8M | 5.08M | 4.67M | 5.32M | 6.23M | 4.65M | 5.29M | 3.97M | 3.61M | 3.27M | 3.7M | 3.35M | 3.61M | 3.51M | 3.53M |
| Sales and Marketing Revenue Growth | +3.51% | +2.26% | -12.70% | +0.34% | +1.52% | +9.23% | +26.57% | -17.78% | -9.79% | -1.25% | +39.58% | -13.01% | -7.80% | +8.83% | +5.07% | +0.47% | -7.18% | +4.25% | -33.71% | +0.55% | +7.94% | +0.64% | -10.30% | +18.85% | -5.38% | +8.69% | -12.18% | -14.58% | +33.76% | -12.06% | +33.41% | +9.76% | +10.46% | -11.54% | +10.43% | -7.18% | +2.95% | -0.72% | n/a |